ATE175210T1 - Ein neues, biologisch aktives vom huhn stammendes peptid (huhn-cnp) - Google Patents

Ein neues, biologisch aktives vom huhn stammendes peptid (huhn-cnp)

Info

Publication number
ATE175210T1
ATE175210T1 AT91115080T AT91115080T ATE175210T1 AT E175210 T1 ATE175210 T1 AT E175210T1 AT 91115080 T AT91115080 T AT 91115080T AT 91115080 T AT91115080 T AT 91115080T AT E175210 T1 ATE175210 T1 AT E175210T1
Authority
AT
Austria
Prior art keywords
chicken
cnp
biologically active
derived peptide
new biologically
Prior art date
Application number
AT91115080T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Original Assignee
Suntory Ltd
Hisayuki Matsuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd, Hisayuki Matsuo filed Critical Suntory Ltd
Application granted granted Critical
Publication of ATE175210T1 publication Critical patent/ATE175210T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91115080T 1990-09-07 1991-09-06 Ein neues, biologisch aktives vom huhn stammendes peptid (huhn-cnp) ATE175210T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2238293A JP2977158B2 (ja) 1990-09-07 1990-09-07 トリ由来新規生理活性ペプチド（ニワトリｃｎｐ）

Publications (1)

Publication Number Publication Date
ATE175210T1 true ATE175210T1 (de) 1999-01-15

Family

ID=17028039

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91115080T ATE175210T1 (de) 1990-09-07 1991-09-06 Ein neues, biologisch aktives vom huhn stammendes peptid (huhn-cnp)

Country Status (8)

Country Link
US (1) US5338830A (de)
EP (1) EP0475291B1 (de)
JP (1) JP2977158B2 (de)
AT (1) ATE175210T1 (de)
DE (1) DE69130696T2 (de)
DK (1) DK0475291T3 (de)
ES (1) ES2127190T3 (de)
GR (1) GR3029628T3 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
KR20070007842A (ko) 2004-03-31 2007-01-16 카즈와 나카오 신장증가용 조성물
EP1759710B1 (de) 2004-03-31 2014-05-07 Kazuwa Nakao Mittel zur behandlung oder prävention von arthritis
ES2365023T3 (es) 2004-04-21 2011-09-20 Enobia Pharma Inc. Conjugados de administración ósea y método de uso de los mismos para dirigir proteínas a hueso.
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
RU2708068C2 (ru) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Лечение судорог с использованием рекомбинантной щелочной фосфатазы
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CN109348717A (zh) * 2015-07-31 2019-02-15 Igisu株式会社 Cnp环肽以及含有该环肽的药物、外用剂和化妆品
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (de) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie
EP3368062A4 (de) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von craniosynostose bei einem patienten
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017173413A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
EP3464573B1 (de) 2016-06-06 2026-03-04 Alexion Pharmaceuticals, Inc. Auswirkungen von metallen auf die herstellung von alkalischen phosphatasen
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
KR20240158374A (ko) 2017-03-31 2024-11-04 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
JP7820148B2 (ja) 2018-08-10 2026-02-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
AU2020398898A1 (en) 2019-12-09 2022-07-21 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
JPH04120094A (ja) 1992-04-21
EP0475291A1 (de) 1992-03-18
EP0475291B1 (de) 1998-12-30
JP2977158B2 (ja) 1999-11-10
DE69130696D1 (de) 1999-02-11
ES2127190T3 (es) 1999-04-16
US5338830A (en) 1994-08-16
DK0475291T3 (da) 1999-08-30
DE69130696T2 (de) 1999-06-10
GR3029628T3 (en) 1999-06-30

Similar Documents

Publication Publication Date Title
ATE175210T1 (de) Ein neues, biologisch aktives vom huhn stammendes peptid (huhn-cnp)
ATE175211T1 (de) Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp)
DE69013313D1 (de) Mehrstufenverfahren zur Herstellung von Hexafluorpropylen.
DE59304248D1 (de) Mehrstufenprozess zur Herstellung von thermoplastisch verarbeitbaren Polyurethan-Elastomeren
DE69300497D1 (de) Silberkatalysator zur Herstellung von Äthylenoxid.
ATE39249T1 (de) Verfahren zur herstellung von polyisocyanatopolyisocyanuraten durch katalytische cyclotrimerisierung von polyisocyanaten.
DE69008326D1 (de) Mehrstufenverfahren zur Herstellung von Hexafluoropropylen.
NO895028L (no) Ny chimerisk transformerende vekstfaktor-beta.
DE3750915D1 (de) Für Antitumor-Polypeptide kodierende DNS, die Polypeptide und diese Polypeptide enthaltenden Antitumor-Wirkstoffe.
DE69219590D1 (de) BPC-Peptide, deren Herstellung und Verwendung
DE69010171D1 (de) Mehrstufenverfahren zur Herstellung von Hexafluoropropylen.
DE69004229D1 (de) Verfahren zur Reinigung von 1,1-Dichlor-1-fluorethan.
DE59102062D1 (de) Verfahren zur biologischen Reinigung von Abluftströmen.
FI101542B1 (fi) Kemiallinen syntetointimenetelmä fibronektiiniä sitovan proteiinin tai polypeptidin valmistamiseksi
DK0544826T3 (da) Overlegne trombomodulinanaloger til farmaceutisk anvendelse
DE59308152D1 (de) Mehrstufenprozess zur Herstellung von thermoplastisch verarbeitbaren Polyurethan-Elastomeren
ATE94588T1 (de) Verfahren zur herstellung und reinigung von alpha-interferon.
ATE133709T1 (de) Peroxidase-gen von mikrobischem ursprung
ATE14126T1 (de) Verfahren zur herstellung von 2-acyl1,3,4,6,7,11b-2h-hexahydro-4-pyrazino(2,1a)isochinolinonen und zwischenprodukte.
ATE47880T1 (de) Vorlaeufer eines an dem c-ende amidierten peptids und dessen herstellung.
DE59008482D1 (de) Verfahren zur Herstellung von 2,4,5-Triamino-6-hydroxypyrimidin durch katalytische Hydrierung von 2,4-Diamino-6-hydroxy-5-nitrosopyrimidin.
DE3780665D1 (de) Mehrstufiges reduktionsverfahren zur herstellung von ferromagnetischem chromdioxid.
DE68910033D1 (de) Katalytisches Verfahren zur Herstellung von optisch-aktiven Alpha-Hydroxycarboxylaten.
ATE102997T1 (de) Thymosin und tnf-kodierende dna.
ATE37865T1 (de) Verfahren zur herstellung von monochloressigsaeure aus glykolsaeure.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee